Pivotal's Ramey Pounds Table On Herbalife

Pivotal Research analyst Tim Ramey, who has a Buy rating on Herbalife Ltd.

shares, maintains that the company would have injunction or consent decree as part of its potential settlement with FTC. "We clearly are moving forward to something …it could be litigation we can take that off the table," Ramey told on CNBC. Ramey says shorting the stock is "absurdly risky" and his $90 price target implies an upside of 54 percent from Thursday's close. Herbalife reported first quarter EPS of $1.36 versus $1.09 estimates and revenue of $1.11 billion versus $1.07 estimates. The company raised its FY2016 adjusted EPS guidance to a range of $4.40 to $4.75, from $4.05 to $4.50 previously. http://www.benzinga.com/news/earnings/16/05/7940805/herbalifes-bullish-trifecta-beat-raise-and-ftc-disclosure-making-investo Ramey added that the "fundamentals still very strong." Shares of were up 9.74 percent to $64.00.